Pharma: Partners in growth? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Partners in growth?

Apr 17, 2006

While pharma companies seem to have left the demons of the past year well behind them, challenges still abound in the global generics arena, in the domestic market and even in discovery research. And this is due to changing fundamentals and business dynamics of the sector. One is the introduction of the product patent law. The other is the increased competition and brutal price erosion in the generics market. Keeping this in mind, pharma companies are looking to forge alliances with global innovators in various aspects of business, be it research, generics or new product launches. In fact, even the stock markets have perceived these 'partnerships' in a favourable light. In this write-up, we shall attempt to find out why.

Alliance with global pharma majors in...
Discovery research: Considering that discovery research is a high-risk, high-return business, Indian pharma companies have been collaborating with global pharma companies in light of the huge investments involved and uncertainty in the outcome. To cite examples, Ranbaxy's anti-malarial molecule, which is currently undergoing Phase II clinical trials, is being developed in collaboration with Medicines for Malaria Venture. Out-licensing of molecules in return for milestone payments is also another commonly followed approach to mitigate the high costs involved in NCE (new chemical entity) research. Also, Glenmark, whose molecule 'Oglemilast', which the company out-licensed to the US-based Forest Labs, has generated considerable interest on the bourses in the past one year. Dr. Reddy's formation of a separate company for carrying out clinical trials has also been touted as a smart move and is expected to contribute to margin expansion going forward.

Contract research: Contract research is also tipped to gain ground in India after the introduction of the product patent law. With considerable pressure on global pharma majors to cut back their R&D costs, a majority of them are looking to shift some of their R&D work to low-cost destinations like India. For example, Biocon has forayed into the custom research business with the formation of two subsidiaries, Syngene and Clinigene. While the contribution of this business to overall revenues (12%) is smaller in comparison to its biopharmaceuticals business (77%), it clocked an impressive 69% YoY and 47% YoY growth in FY05 and 9mFY06 indicating the potential for growth in this field.

Generics: While much as been said about authorised generics and the bane it is to generic companies aiming for that increasingly elusive 180-day exclusivity period, there is also a silver lining. This holds true if it is an Indian pharma company authorised to sell the generic version. Dr. Reddy's has entered into an authorised generics deal with Merck for the latter's drug 'Simvastatin' and will benefit immensely on the revenue front if the exclusivity period is granted to the challenging company.

Contract manufacturing: While Ranbaxy and Dr. Reddy's are directly competing in the global generics market, Cipla has entered into alliances with global generic majors such as Ivax, Watson and Mylan to capitalise on the huge generics opportunity in the coming years. In this case, the company is providing low cost bulk drugs to these generic companies and is at the same time obviating any need in incurring expenses in filing ANDAs. This has ensured a relatively stable revenue stream for Cipla as compared to either Ranbaxy or Dr. Reddy's.

New product launches: In the product patent era, in-licensing agreements with global pharma companies is beneficial in stepping up new product launches in the country. Players such as GSK Pharma, Ranbaxy, Nicholas Piramal, which have a strong marketing and distribution network have an edge over their peers in bagging such deals. Such deals also enable players to widen their product portfolio and consequently boost topline growth.

To sum up...
In our view, willingness of Indian pharma companies to bring outside expertise to the table should be construed as a positive step to stabilise revenues and profitability. However, there is also a catch to the situation. This is because as revenues have to be 'shared', the potential upside gets capped. However, considering the volatile performance of some of the domestic pharma majors over the past few years, stability in business has assumed paramount importance. At the end of the day, a solid foundation is what will pave the way for a higher growth and consequently rewarding returns for investors in the long run.

Equitymaster requests your view! Post a comment on "Pharma: Partners in growth?". Click here!

  

More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime (Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Nov 26, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS